CHRS
Price
$1.35
Change
-$0.08 (-5.59%)
Updated
Dec 12 closing price
Capitalization
163.18M
94 days until earnings call
Intraday BUY SELL Signals
IPSC
Price
$0.56
Change
-$0.03 (-5.08%)
Updated
Dec 12 closing price
Capitalization
48.75M
89 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CHRS vs IPSC

Header iconCHRS vs IPSC Comparison
Open Charts CHRS vs IPSCBanner chart's image
Coherus Oncology
Price$1.35
Change-$0.08 (-5.59%)
Volume$872.12K
Capitalization163.18M
Century Therapeutics
Price$0.56
Change-$0.03 (-5.08%)
Volume$501.97K
Capitalization48.75M
CHRS vs IPSC Comparison Chart in %
CHRS
Daily Signal:
Gain/Loss:
IPSC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CHRS vs. IPSC commentary
Dec 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a StrongBuy and IPSC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 14, 2025
Stock price -- (CHRS: $1.43 vs. IPSC: $0.59)
Brand notoriety: CHRS and IPSC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 96% vs. IPSC: 89%
Market capitalization -- CHRS: $163.18M vs. IPSC: $48.75M
CHRS [@Biotechnology] is valued at $163.18M. IPSC’s [@Biotechnology] market capitalization is $48.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileIPSC’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • IPSC’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than IPSC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while IPSC’s TA Score has 8 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 6 bearish.
  • IPSC’s TA Score: 8 bullish, 3 bearish.
According to our system of comparison, IPSC is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а +16.26% price change this week, while IPSC (@Biotechnology) price change was +12.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

CHRS is expected to report earnings on Mar 17, 2026.

IPSC is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($163M) has a higher market cap than IPSC($48.7M). CHRS YTD gains are higher at: 3.623 vs. IPSC (-41.426). CHRS has higher annual earnings (EBITDA): 90.2M vs. IPSC (-909K). CHRS has more cash in the bank: 192M vs. IPSC (133M). CHRS has less debt than IPSC: CHRS (40.7M) vs IPSC (45M). CHRS has higher revenues than IPSC: CHRS (278M) vs IPSC (113M).
CHRSIPSCCHRS / IPSC
Capitalization163M48.7M335%
EBITDA90.2M-909K-9,923%
Gain YTD3.623-41.426-9%
P/E Ratio2.45N/A-
Revenue278M113M246%
Total Cash192M133M144%
Total Debt40.7M45M90%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
6
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
87
SEASONALITY SCORE
1..100
6

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSIPSC
RSI
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 5 days ago
83%
Declines
ODDS (%)
Bearish Trend 24 days ago
88%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 4 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signal:
Gain/Loss:
IPSC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MLMC1.750.07
+4.46%
Mike Lindell Media Corp.
EPIPF19.15N/A
N/A
Epiroc Aktiebolag
ABSOF0.03N/A
N/A
ABS-CBN Holdings Corp
TOSCF16.00N/A
N/A
Tosoh Corp.
MCEM225.87-0.10
-0.04%
Monarch Cement Co. (The)

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with RXRX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+7.52%
RXRX - CHRS
47%
Loosely correlated
-3.98%
BEAM - CHRS
47%
Loosely correlated
+0.40%
XENE - CHRS
45%
Loosely correlated
+0.51%
VRDN - CHRS
43%
Loosely correlated
-0.09%
IPSC - CHRS
42%
Loosely correlated
N/A
More

IPSC and

Correlation & Price change

A.I.dvisor indicates that over the last year, IPSC has been loosely correlated with CDXS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IPSC jumps, then CDXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPSC
1D Price
Change %
IPSC100%
N/A
CDXS - IPSC
50%
Loosely correlated
-6.04%
CRSP - IPSC
49%
Loosely correlated
+0.87%
SYRE - IPSC
49%
Loosely correlated
-0.87%
IMNM - IPSC
48%
Loosely correlated
-3.99%
RXRX - IPSC
47%
Loosely correlated
-3.98%
More